Wolfe Research downgraded Insulet from Outperform to Peer Perform
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/16/2025 | $365.00 | Buy | Truist |
| 5/30/2025 | $380.00 | Buy | Goldman |
| 5/13/2025 | $350.00 | Peer Perform → Outperform | Wolfe Research |
| 4/29/2025 | Outperform → Peer Perform | Wolfe Research | |
| 3/6/2025 | $340.00 | Outperform | RBC Capital Mkts |
| 11/6/2024 | $300.00 | Outperform | Bernstein |
| 5/30/2024 | $235.00 | Buy | Redburn Atlantic |
| 5/7/2024 | $200.00 | Peer Perform → Outperform | Wolfe Research |
Truist initiated coverage of Insulet with a rating of Buy and set a new price target of $365.00
Goldman initiated coverage of Insulet with a rating of Buy and set a new price target of $380.00
Wolfe Research upgraded Insulet from Peer Perform to Outperform and set a new price target of $350.00
4 - INSULET CORP (0001145197) (Issuer)
4 - INSULET CORP (0001145197) (Issuer)
4 - INSULET CORP (0001145197) (Issuer)